Trial Profile
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY- EXTended treatment. The AMPLIFY-EXT study) [Extension of 700032384]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms AMPLIFY-EXT
- Sponsors Bristol-Myers Squibb
- 16 May 2022 Data from ARISTOTLE: NCT00412984; AVERROES: NCT00496769; AMPLIFY: NCT00643201; AMPLIFY-EXT: NCT00633893; ADVANCE-1: NCT00371683; ADVANCE-2: NCT00452530; ADVANCE-3: NCT00423319 studies has been used to assess apixaban use in obese patients published in the American Journal of Cardiovascular Drugs
- 12 Sep 2016 Results of this and two other trials (AMPLFY and AMPLIFY J) published in the Drugs (2016).
- 08 Oct 2015 Results published in the Thrombosis and Haemostasis